Biotechnology company developing new medicines to treat rare disorders of calcification with initial focus on enzyme replacement therapy for devastating and debilitating rare diseases that largely impact infants, children and young adults.
- Year invested 2017
- Investment Stage Early
- Board Members
- Sectors
- Investment Status Current
- Website inozyme.com/
- Company Status IPO/Public (NASDAQ: INZY)